News

Filter

Current filters:

dabrafenibDiabetes

1 to 9 of 95932 results

Prescribing habits for biosimilars will depend on robust clinical trials and manufacturer reputation

Prescribing habits for biosimilars will depend on robust clinical trials and manufacturer reputation

28-08-2014

Physicians across six different specialties expect that they will base prescribing decisions for biosimilars…

BiosimilarsBiotechnologyDecision Resources GroupMarkets & Marketing

UK NICE wants more info on type 2 diabetes drug Jardiance

UK NICE wants more info on type 2 diabetes drug Jardiance

28-08-2014

In a new draft guidance issued today, the UK drugs watchdog the National Institute for Health and Care…

Boehringer IngelheimDiabetesEli LillyJardiancePharmaceuticalPricingRegulationUK

Bristol-Myers’ hep C drug Daklinza approved in Europe

Bristol-Myers’ hep C drug Daklinza approved in Europe

27-08-2014

US pharma major Bristol-Myers Squibb says that the European Commission has approved Daklinza (daclatasvir),…

Anti-viralsBristol-Myers SquibbDaklinzaEuropeGilead SciencesPharmaceuticalRegulationSovaldi

FDA priority review for Amgen’s ivabradine in CHF

FDA priority review for Amgen’s ivabradine in CHF

27-08-2014

The US Food and Drug Administration has granted priority review designation for US biotech giant Amgen’s…

AmgenBiotechnologyCardio-vascularivabradineRegulationServierUSA

Amerigen Pharma and Ningbo Menovo link up on generics for US market

27-08-2014

US generic drugmaker Amerigen Pharmaceuticals and China’s Ningbo Menovo Pharmaceutical have entered…

Amerigen PharmaceuticalsChinaGenericsNingbo MenovoProductionResearchUSA

NICE recommends Biogen Idec’s Tecfidera for multiple sclerosis

NICE recommends Biogen Idec’s Tecfidera for multiple sclerosis

27-08-2014

The UK’s drugs watch dog, the National Institute for Health and Care Excellence (NICE), has recommended…

Biogen IdecBiotechnologyCNS DiseasesMultiple sclerosisRegulationTecfideraUK

1 to 9 of 95932 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top